DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives $15.15 Consensus PT from Brokerages

02 Jan 2026, 06:10 by Teresa Graham · The Cerbat Gem

DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Get Free Report) has earned a consensus rating of “Reduce” from the fifteen analysts that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $15.1538.

A number of equities research analysts recently issued reports on the stock. Robert W. Baird decreased their price target on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Tuesday, December 16th. UBS Group decreased their target price on shares of DENTSPLY SIRONA from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, October 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of DENTSPLY SIRONA in a report on Friday, September 26th. Barclays assumed coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price target for the company. Finally, Evercore ISI lowered their price objective on DENTSPLY SIRONA from $17.00 to $13.00 and set an “in-line” rating for the company in a research note on Wednesday, October 8th.

Check Out Our Latest Analysis on XRAY

DENTSPLY SIRONA Trading Up 0.3%

Shares of DENTSPLY SIRONA stock opened at $11.43 on Friday. DENTSPLY SIRONA has a twelve month low of $9.85 and a twelve month high of $20.59. The company has a quick ratio of 0.99, a current ratio of 1.47 and a debt-to-equity ratio of 1.36. The business has a 50-day moving average price of $11.41 and a 200-day moving average price of $13.31. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -2.59, a PEG ratio of 0.84 and a beta of 1.00.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.08). DENTSPLY SIRONA had a negative net margin of 24.34% and a positive return on equity of 17.10%. The firm had revenue of $904.00 million for the quarter, compared to the consensus estimate of $900.33 million. During the same period in the previous year, the company posted $0.50 earnings per share. DENTSPLY SIRONA’s quarterly revenue was down 4.9% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. Equities research analysts anticipate that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 9th. Investors of record on Friday, December 26th will be given a $0.16 dividend. The ex-dividend date is Friday, December 26th. This represents a $0.64 dividend on an annualized basis and a yield of 5.6%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is currently -14.48%.

Insider Buying and Selling

In other DENTSPLY SIRONA news, Director Gregory T. Lucier sold 82,200 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

Large investors have recently made changes to their positions in the company. AQR Capital Management LLC raised its position in DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the period. Armistice Capital LLC boosted its position in shares of DENTSPLY SIRONA by 1,044.0% during the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after buying an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of DENTSPLY SIRONA by 662.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after buying an additional 4,003,606 shares during the last quarter. Norges Bank purchased a new stake in shares of DENTSPLY SIRONA in the second quarter worth approximately $39,700,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares during the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Company Profile

(Get Free Report)

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.